Literature DB >> 24462178

Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: a multicenter study in Korea.

Tark Kim1, Yong Pil Chong2, Seong Yeon Park3, Min-Hyok Jeon4, Eun Joo Choo5, Jin-Won Chung6, Hyun Kyung Lee7, Chisook Moon8, Dong-Min Kim9, Kyong Ran Peck10, Yang Soo Kim11.   

Abstract

We performed a case-control study to identify risk factors of carbapenem-resistant Gram-negative bacteria (CRGNB) as an increasing cause of hospital-acquired pneumonia (HAP). The study included critically ill adult patients with HAP whose microbial etiology was identified at eight tertiary centers in Korea between June 2008 and December 2009. Eighty two patients with 86 isolates of CRGNB (62 Acinetobacter baumannii, 14 Pseudomonas aeruginosa, and 10 Stenotrophomonas maltophilia) were included in the case group, and 122 patients with carbapenem-susceptible Gram-negative bacteria were included in the control group. Diabetes mellitus (adjusted odds ratio [aOR] 2.82, 95% confidence interval [95% CI] 1.25-6.38), radiologic score ≥5 (aOR 4.56, 95% CI 2.36-8.81), prior fluoroquinolone (aOR 2.39. 95% CI = 1.07-5.35), or carbapenem usage (aOR 2.82, 95% CI 1.75-17.83) were found to be independent risk factors. Fluoroquinolone and carbapenem should be cautiously used to avoid HAP caused by CRGNB.
© 2014.

Entities:  

Keywords:  Carbapenem-resistant Gram-negative bacteria; Hospital-acquired pneumonia; Risk factor

Mesh:

Substances:

Year:  2014        PMID: 24462178     DOI: 10.1016/j.diagmicrobio.2013.08.011

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  12 in total

1.  Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.

Authors:  Zubair A Qureshi; Lauren E Hittle; Jessica A O'Hara; Jesabel I Rivera; Alveena Syed; Ryan K Shields; Anthony W Pasculle; Robert K Ernst; Yohei Doi
Journal:  Clin Infect Dis       Date:  2015-01-28       Impact factor: 9.079

2.  Similar frequencies of Pseudomonas aeruginosa isolates producing KPC and VIM carbapenemases in diverse genetic clones at tertiary-care hospitals in Medellín, Colombia.

Authors:  Johanna M Vanegas; Astrid V Cienfuegos; Ana M Ocampo; Lucelly López; Helena del Corral; Gustavo Roncancio; Patricia Sierra; Lina Echeverri-Toro; Sigifredo Ospina; Natalia Maldonado; Carlos Robledo; Andrea Restrepo; J Natalia Jiménez
Journal:  J Clin Microbiol       Date:  2014-09-10       Impact factor: 5.948

3.  Genetic Manipulation of Stenotrophomonas maltophilia.

Authors:  Elliott Welker; Yayra Domfeh; Deepti Tyagi; Sanjivni Sinha; Nathan Fisher
Journal:  Curr Protoc Microbiol       Date:  2015-05-01

4.  Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.

Authors:  Xiaomai Wu; Yefei Zhu; Qiuying Chen; Liuyang Gong; Jian Lin; Dongqing Lv; Jiaxi Feng
Journal:  Biomed Res Int       Date:  2016-12-04       Impact factor: 3.411

5.  High prevalence and clonal dissemination of OXA-72-producing Acinetobacter baumannii in a Chinese hospital: a cross sectional study.

Authors:  Yong Chen; Yuying Yang; Lin Liu; Guangbin Qiu; Xuelin Han; Shuguang Tian; Jingya Zhao; Fangyan Chen; Hajo Grundmann; Haifeng Li; Jinke Sun; Li Han
Journal:  BMC Infect Dis       Date:  2018-09-29       Impact factor: 3.090

Review 6.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640

7.  Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.

Authors:  Won-Young Kim; Jae-Young Moon; Jin Won Huh; Sang-Ho Choi; Chae-Man Lim; Younsuck Koh; Yong Pil Chong; Sang-Bum Hong
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

8.  Acquisition and clearance of multidrug resistant Acinetobacter baumannii on healthy young adults concurrently burned in a dust explosion in Taiwan: the implication for antimicrobial stewardship.

Authors:  Po-Yen Huang; Shian-Sen Shie; Jung-Jr Ye; Shih-Pin Lin; Tsui-Ping Liu; Ting-Shu Wu; Tsu-Lan Wu; Shiow-Shuh Chuang; Ming-Huei Cheng; Yu-Chia Hsieh; Ching-Tai Huang
Journal:  BMC Infect Dis       Date:  2017-08-30       Impact factor: 3.090

9.  Risk factors of multidrug-resistant Acinetobacter baumannii recurrence after successful eradication in ventilated patients.

Authors:  Chiung-Yu Lin; Yu-Mu Chen; Meng-Chih Lin; Yu-Ping Chang; Tung-Ying Chao; Chin-Chou Wang; Yuh-Chyn Tsai; Lien Shi Shen; Chin-Ling Li; An-Shen Lin
Journal:  Biomed J       Date:  2016-06-10       Impact factor: 4.910

10.  Unlocking NuriPep 1653 From Common Pea Protein: A Potent Antimicrobial Peptide to Tackle a Pan-Drug Resistant Acinetobacter baumannii.

Authors:  Niamh Maire Mohan; Amine Zorgani; Gael Jalowicki; Alish Kerr; Nora Khaldi; Marta Martins
Journal:  Front Microbiol       Date:  2019-09-18       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.